Company: Teva Pharmaceuticals Ireland.
Legal category: Prescription. GMS reimburseable. Sport permitted.
Active ingredient: Tiotropium (as bromide) 10mcg per delivered dose.
Description: Hard capsule containing inhalation powder for use with Zonda device.
Presentation: 30 + Zonda inhaler, €28.93.
Indications: Maintenance bronchodilator treatment to relieve symptoms of chronic obstructive pulmonary disease (COPD).
Pharmacology: Tiotropium, an anticholinergic, is a long-acting, specific muscarinic receptor antagonist which competitively and reversibly binds to M3 receptors in bronchial smooth musculature, antagonising the cholinergic (bronchoconstrictive) effects of acetylcholine, resulting in bronchial smooth muscle relaxation.
Dosage: Adult: Inhale one capsule once daily with Zonda inhaler at same time each day (maximum). Elderly: As per adults. Children: Under 18 years, not recommended.
Contraindications: Hypersensitivity to the active ingredient or to any of the excipients.
Special precautions: Not for use in acute episodes of bronchospasm. Immediate hypersensitivity reactions may occur after administration. Discontinue immediately if paradoxical bronchospasm occurs. Caution: Narrow-angle glaucoma, prostatic hyperplasia, bladder-neck obstruction, recent myocardial infarction <6 months, unstable or life-threatening cardiac arrhythmia requiring intervention or a change in drug therapy in the past year, hospitalisation for heart failure during previous year. May be associated with dental caries with long term use. Moderate-severe renal impairment (assess risk/benefit). Discontinue and seek immediate specialist advice if eye symptoms develop. Driving/using machines (dizziness, blurred vision). Pregnancy (avoid), lactation (assess risk/benefit).Contains lactose.
Drug interactions: Not recommended: Other anticholinergics.
Adverse drug reactions: Dry mouth.
Full prescribing information and references available from Teva Pharmaceuticals Ireland. Telephone: 1800 201700.
The post Braltus appeared first on Irish Medical Times.